Related Experiment Video

Updated: Oct 4, 2025

Refined Murine Model of Idiopathic Pulmonary Fibrosis
07:51

Refined Murine Model of Idiopathic Pulmonary Fibrosis

Published on: June 17, 2025

373

Identification of targetable kinases in idiopathic pulmonary fibrosis

Hisao Higo1, Kadoaki Ohashi2, Shuta Tomida3

  • 1Department of Hematology, Oncology and Respiratory Medicine, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine, Okayama, Japan.

Respiratory Research
|February 8, 2022
PubMed
Abstract

Insights

This study identified DCLK1 and STK33 as potential therapeutic targets for idiopathic pulmonary fibrosis (IPF). Other kinases like PDK4, ERBB4, PIM2, and SYK may offer personalized IPF treatment options.

Area of Science:

  • Pulmonary Medicine
  • Molecular Biology
  • Oncology

Background:

  • Tyrosine kinase activation is crucial in pulmonary fibrosis progression.
  • Idiopathic pulmonary fibrosis (IPF) requires novel therapeutic targets.
  • Kinase gene expression profiling can identify potential IPF treatments.

Purpose of the Study:

  • To analyze kinase gene expression in IPF lung tissue.
  • To identify potential molecular targets for IPF therapy.
  • To explore personalized treatment strategies for IPF.

Main Methods:

  • Next-generation sequencing of 612 kinase and cancer-related genes.
  • Analysis of 13 IPF lung tissue samples and 8 control samples.
  • Confirmation of gene expression using immunohistochemistry (IHC).

Main Results:

  • Gene expression correlated with fibrosis severity (Ashcroft score).
  • IPF lung samples showed greater heterogeneity than controls.
  • DCLK1 and STK33 were upregulated in IPF samples; other kinases varied by case.

Conclusions:

  • DCLK1 and STK33 are promising targets for IPF molecular therapy.
  • PDK4, ERBB4, PIM2, and SYK may serve as personalized IPF targets.
  • Further large-scale studies are needed for personalized IPF therapies.
Keywords:
Idiopathic pulmonary fibrosisMolecular therapeutic targetPersonalized therapyRNA sequencing

More Related Videos

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

8.0K
A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

15.0K

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
4.1K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
273
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
3.1K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
9.5K
Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
312